CSE's Barrington Miller was recently joined by Christopher Moreau, CEO of Algernon Pharmaceuticals Inc. (CSE:AGN), to discuss his company's work to develop NP-120 (Ifenprodil) as a new therapeutic in the fight against COVID-19.

In this discussion, Chris outlines how his company focuses on drug re-purposing, a term that is widely understood through the example provided by Viagra (1:04), the important distinction between therapeutic treatments and anti-virals and vaccines (12:14), and why the "grandaddy" of all market approvals is from the USFDA (18:25).

Listen until the end to hear how the company's name is actually inspired by the title of a science fiction novel, and how the company has a history of investigating compounds developed by the Soviet Union!

(Subsequent to this chat, Algernon announced Health Canada approval to move forward with its PH2b/3 trial here with Ifenprodil as a potential treatment for COVID-19.)

Related Link
algernonpharmaceuticals.com

🔴 Subscribe for more great CSE insights and interviews here: https://go.thecse.com/CSETV-Subscribe

#alwaysinvested

STAY CONNECTED WITH THE CSE
=============================

📧 - NEWSLETTER: https://go.thecse.com/CSE-Mailing-List-Subscribe
🎧 - PODCAST: https://blog.thecse.com/cse-podcasts/
📸 - INSTAGRAM: https://www.instagram.com/canadianexchange/
🤝 - LINKEDIN: https://ca.linkedin.com/company/canadian-securities-exchange
👥 - FACEBOOK: https://www.facebook.com/CanadianSecuritiesExchange/
🐦 - X: https://x.com/CSE_News
📝 - BLOG: https://blog.thecse.com/
🖥 - WEBSITE: https://thecse.com/
📖 - MAGAZINE: https://issuu.com/thecse/docs

©2024 CNSX Markets Inc. All rights reserved.